N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=20 Hypnotherapy for Treatment of Overactive Bladder
Overactive Bladder
Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07
Phase 4 N=42 Validation of a Real-time Urodynamic Measure of Urinary Urgency
Overactive Bladder Syndrome
Primary: Change in Maximal Cystometric Capacity (mL) — 95; 473.50 milliliters (mL) — p=.005
Phase 2 N=550 SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
Overactive Bladder Syndrome (OABS)
Primary: Change From Baseline to Week 8 in the Number of Voids/24 Hours — -1.06; -1.44; -1.78; -2.41 voids/24 hrs.
Phase 4 N=963 A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
Overactive Bladder
Primary: Mean Number of Micturition-related Nocturnal Urgency Episodes Per 24 Hours — 2.93; 2.91 episodes per 24 hours
Phase 3 N=883 Fesoterodine Flexible Dose Study
Overactive Bladder
Primary: Change in Mean Number of Micturition Episodes Per 24 Hours at Week 12 Relative to Baseline. — -2.1; -2.9 number of episodes per 24 hours — p=0.0002
N/A N=96 FREEOAB Study for Overactive Bladder
Overactive Bladder · Urinary Frequency · Urinary Incontinence, Urge
Primary: Percentage of Responders in Voiding (Urinary Frequency) Events — 55 Participants
Phase 2 N=80 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Overactive Bladder With Urge Urinary Incontinence
Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722
N/A N=74 Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
Overactive Bladder
Primary: Change in Mean Daily Urgency Incontinence Episodes — -2.5; -2.5 number of incontinence episodes/24 hours
Phase 3 N=143 Behavioral Treatment of Overactive Bladder in Men
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
Phase 4 N=127 Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Obesity · Overactive Bladder · Incontinence
Primary: Percent Change From Baseline in Urinary Urgency Incontinence (UUI) — -23.7; 57.8 Percent change
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 3 N=1,105 Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Overactive Bladder
Primary: Change From Baseline at Week 12 in the Average Number of Micturition Episodes Per Day — -2.04; -1.30 Micturitions per day — p=<0.0001
Phase 4 N=566 A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
Overactive Bladder
Primary: Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours — 3.93; 4.07 episodes per 24 hours
Phase 4 N=70 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)
Overactive Bladder
Primary: Change in Mean Number of Micturition Episodes Per 24 Hours — -1.9; -2.2 episodes
Phase 4 N=17 An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
Bladder Outlet Obstruction
Primary: IPSS Obstructive — 9.1; 7.5; 8.4; 7.9 units on a scale
N/A N=20 A Trial of Transcutaneous Nerve Stimulation for OAB
Overactive Bladder
Primary: Patient Reported Outcome Measure (Patient Percention of Bladder Condition Question) — 4; 3 units on a scale
N/A N=163 Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
Overactive Bladder
Primary: Evaluate Proportion of Responders Based on the Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups…
Phase 4 N=132 Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence
Urinary Bladder, Overactive
Primary: Change in OAB Symptoms Post Pubovaginal Sling Operation — 63; 21; 4 participants — p=0.001
N/A N=18 Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
Overactive Bladder
Primary: Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation — 8; 1 participants
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 3 N=1,518 A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
Overactive Bladder
Primary: Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants — -1.3; -1.8; -1.6 micturitions per…
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
Phase 2 N=134 Bacterial Genomic Sequencing in Overactive Bladder
Overactive Bladder
Primary: Bacterial Genomic Sequencing — 25; 11; 3; 6 participants
Phase 4 N=376 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
Overactive Bladder (OAB)
Primary: Participants Tolerability Assessed by the Medication Tolerability Scale of the Overactive Bladder-Satisfaction (OAB-S) Questionnaire at the End of Treatment (EOT)…
Phase 4 N=147 InSite for Over Active Bladder
Urinary Incontinence, Urgency-frequency · Overactive Bladder
Primary: Randomized Cohort: OAB Therapeutic Response — 61; 42 percentage of participants with response — p=0.016
Phase 3 N=947 Fesoterodine "add-on" Male Overactive Bladder Study
Overactive Bladder Syndrome
Primary: Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12 — -3.2; -2.9 number of episodes — p=0.1959
N/A N=18 Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Overactive Bladder
Primary: Change in Urge Incontinence Episodes — 3.9 UUI